---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-002863"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:23:02.597328+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics prices $125M public offering of 35.7M shares at $3.50; uplists to Nasdaq

## Summary
- Underwritten public offering of 35,715,000 shares at $3.50/share; underwriters have 30-day option for additional 5,357,250 shares.
- Gross proceeds ~$125M; net proceeds after discounts and expenses ~$117.3M.
- Common stock to trade on Nasdaq Capital Market under ticker CMPX starting November 2, 2021.
- SVB Leerink is book-running manager; Raymond James, Wedbush, H.C. Wainwright as passive book-runners.
- Net proceeds to fund ongoing operations including clinical trials.

## SEC filing metadata
- accession: 0000950170-21-002863
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000095017021002863/0000950170-21-002863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000095017021002863/cmpx-20211101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-002863
- JSON: https://secwatch.observer/filing/0000950170-21-002863.json
- Plain text: https://secwatch.observer/filing/0000950170-21-002863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.